Fair returns on investment are essential for the proper functioning of the private sector, but the extension of the protection of intellectual property rights to biotechnology has led to a growing public perception in some countries that biotech research purely benefits commercial interests and offers no long-term public good. Just as seriously, it also led to a virtual monopoly of GM traits in some parts of the world, by a restricted number of companies, which limits innovation and investment in the technology.